Journal of International Oncology››2019,Vol. 46››Issue (12): 718-722.doi:10.3760/cma.j.issn.1673-422X.2019.12.003
• Original Articles •Previous ArticlesNext Articles
Yu Xuejuan1, An Hongwei2, Sun Yamei3, Jiang Zheng4, Zhang Xuehai5, Yang Wenjing1, Zhang Wei6
1Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan 250012, China;
2Department of Neurosurgery, Lingcheng District Hospital of Traditonal Chinese Medicine of Dezhou, Shandong Province, Dezhou 253500, China;
3Department of Health Management, Zhucheng People’s Hospital, Shandong Province, Zhucheng 262200, China;
4Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan 250012, China;
5Department of Intensive Care Unit, Qilu Hospital of Shandong University, Jinan 250012, China;
6Department of Neurosurgery, Yidu Central Hospital of Weifang, Shandong Province, Weifang 262500, China
Received:
2019-07-31Revised:
2019-10-22Online:
2019-12-08Published:
2019-12-09Contact:
Zhang Wei E-mail:doctorzw@126.comSupported by:
Yu Xuejuan, An Hongwei, Sun Yamei, Jiang Zheng, Zhang Xuehai, Yang Wenjing, Zhang Wei. Expressions of MMP2, TIMP2, Ki-67 and P53 in glioma tissues and their significance[J]. Journal of International Oncology, 2019, 46(12): 718-722.
[1] | Könnecke H, Bechmann I. The role of microglia and matrix metalloproteinases involvement in neuroinflflammation and gliomas[J]. Clin Dev Immunol, 2013, 2013: 914104. DOI: 10.1155/2013/914104. |
[2] | Sato H, Takino T. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion[J]. Cancer Sci, 2010, 101(4): 843-847. DOI: 10.1111/j.1349-7006.2010.01498.x. |
[3] | Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma[J]. Cell, 2013, 155(2): 462-477. DOI: 10.1016/j.cell.2013.09.034. |
[4] | Lu X, Duan L, Xie H, et al. Evaluation of MMP-9 and MMP-2 and their suppressor TIMP-1 and TIMP-2 in adenocarcinoma of esophagogastric junction[J]. Onco Targets Ther, 2016, 9: 4343-4349. DOI: 10.2147/OTT.S99580. |
[5] | Schröder R, Feisel KD, Ernestus RI. Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas[J]. J Neurooncol, 2002, 56(2): 127-132. DOI: 10.1023/a:1014527929948. |
[6] | Mullerat J, Deroide F, Winslet MC, et al. Proliferation and p53 expression in anal cancer precursor lesions[J]. Anticancer Res, 2003, 23(3C): 2995-2999. |
[7] | Liu M, Lawson G, Delos M, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations[J]. Head Neck, 2003, 25(4): 280-288. DOI: 10.1002/hed.10218. |
[8] | Arshad H, Ahmad Z, Hasan SH. Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival[J]. Asian Pac J Cancer Prev, 2010, 11(6): 1637-1640. |
[9] | 魏方, 强铭, 吴陈新, 等. VEGF、Ki-67在人脑胶质瘤中的表达及恶性程度相关性分析[J]. 中国临床实用医学, 2016, 7(2): 56-58. DOI: 10.3760/cma.j.issn.1673-8799.2016.02.016. |
[10] | Bartussek C, Naumann U, Weller M. Accumulation of mutant p53 (V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status[J]. Exp Cell Res, 1999, 253(2): 432-439. DOI: 10.1006/excr.1999.4654. |
[11] | Romano FJ, Guadagno E, Solari D, et al. ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: a clinicopathologic study[J]. J Cell Biochem, 2018, 119(6): 4867-4877. DOI: 10.1002/jcb.26699. |
[12] | Jiang XJ, Lin J, Cai QH, et al. CDH17 alters MMP-2 expression via canonical NF-κB signalling in human gastric cancer[J]. Gene, 2019, 682: 92-100. DOI: 10.1016/j.gene.2018.05.042. |
[13] | Xu J, E C, Yao Y, et al. Matrix metalloproteinase expression and molecular interaction network analysis in gastric cancer[J]. Oncol Lett, 2016, 12(4): 2403-2408. DOI: 10.3892/ol.2016.5013. |
[14] | Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression[J]. FASEB J, 2002, 16(6): 555-564. DOI: 10.1096/fj.01-0790com. |
[15] | Pei J, Park IH, Ryu HH, et al. Sublethal dose of irradiation enhances invasion of malignant glioma cells through p53-MMP2 pathway in U87MG mouse brain tumor model[J]. Radiat Oncol, 2015, 10: 164. DOI: 10.1186/s13014-015-0475-8. |
[16] | Yi GZ, Feng WY, Zhou Q, et al. The impact of MMP-2 and its specific inhibitor TIMP-2 expression on the WHO grade and prognosis of gliomas in Chinese population: a meta-analysis[J]. Mol Neurobiol, 2017, 54(1) :22-30. DOI: 10.1007/s12035-015-9539-x. |
[17] | Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation[J]. J Biol Chem, 2001, 276(10): 7549-7558. DOI: 10.1074/jbc.M010242200. |
[18] | Yi X, Guo J, Guo J, et al. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion[J]. Sci Rep, 2017, 7(1): 3568. DOI: 10.1038/s41598-017-03362-z. |
[19] | Pietruszewska W, Bojanowska-Poźniak K, Kobos J. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study[J]. Otolaryngol Pol, 2016, 70(3): 32-43. DOI: 10.5604/00306657.1202546. |
[20] | Wang Z, Wang B, Shi Y, et al. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2[J]. Oncogene, 2015, 34(11): 1407-1419. DOI: 10.1038/onc.2014.75. |
[21] | Valacca C, Tassone E, Mignatti P. TIMP-2 interaction with MT1-MMP activates the AKT pathway and protects tumor cells from apoptosis[J]. PLoS One, 2015, 10(9): e0136797. DOI: 10.1371/journal.pone.0136797. |
[1] | Lu Huiling, Ji Shengjun, Fu Zhaoyi, Zhang Min.Application of18F-FDG PET-CT in evaluating the prognosis of locally advanced non-small cell lung cancer[J]. Journal of International Oncology, 2019, 46(12): 728-733. |
[2] | Shen Jingxia, Han Bin, Wang Shuying, Kang Haili, Wang Lidong, Liu Xuhui, Cui Qinggui.Clinical efficacy of S-1 combined with gefitinib in the treatment of advanced NSCLC with EGFR-TKI acquired drug resistance[J]. Journal of International Oncology, 2019, 46(12): 723-727. |
[3] | Li Zhengmin, Zhang Yuming, Zhang Zhen, Zhang Ru, Zhu Jing, Wang Jun.Mitochondrial energy metabolism mediatedviaHIF-1 involves the proliferation and apoptosis of renal clear cell carcinoma cells regulated by propofol[J]. Journal of International Oncology, 2019, 46(12): 711-717. |
[4] | Xiong Bobo, Zhang Jinsong, Li Ning, Wang Haifeng, Zuo Yigang, Wang Jiansong.Molecular targeted therapy for advanced kidney cancer[J]. Journal of International Oncology, 2019, 46(12): 705-710. |
[5] | Shen Qinglin, Song Qibin, Zhang Bicheng, Yao Yi, Xu Tangpeng, Chu Yuxin, Peng Min.Effects of microRNA-134 on proliferation and apoptosis of non-small cell lung cancer by regulating P53 protein[J]. Journal of International Oncology, 2018, 45(11): 647-651. |
[6] | Ai Xiaoqing, Jia Xihua, Wang Xiaobo, Zheng Shujun, Zhao Xia, Zhang Bingxin.Expressions of UHRF1, P53 and their clinical significances in colon carcinoma[J]. Journal of International Oncology, 2016, 43(5): 346-349. |
[7] | LAI Jun, LUO Lin.Expression and clinical significance of MGMT, Ki 67 and P53 in human gliomas[J]. Journal of International Oncology, 2015, 42(3): 169-171. |
[8] | WU Zhi, PAN Xiao-Ling, ZHONG Jie.Expressions of MMP-2 and MMP-9 in esophageal cancer[J]. Journal of International Oncology, 2013, 40(8): 708-711. |
[9] | HOU Qing-Sheng, ZHANG Yu-Lin, CHEN De-Xi, GUO Hong-Liang.Role of P53 outside the nucleus[J]. Journal of International Oncology, 2012, 39(8): 665-668. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||